Literature DB >> 34731264

Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND).

Alessandro Nini1,2,3, Matthias Boschheidgen4, Andreas Hiester5, Christian Winter5, Gerald Antoch4, Lars Schimmöller4, Peter Albers5.   

Abstract

PURPOSE: To evaluate the probability to correctly predict major vascular surgery (MVS) in patients undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for testicular cancer.
METHODS: From a database of 504 RPLNDs performed in 434 patients (2008-2018), 78 patients submitted to PC-RPLND for non-seminoma germ-cell cancer after cisplatin-based chemotherapy with available preoperative CT scans were identified. Second PC-PLNDs (Re-Dos), salvage RPLNDs, or RPLNDs for late-relapse were excluded as well as thoraco-abdominal approaches. Preoperative imaging was reviewed by a urologist and a radiologist blinded to operative details.
RESULTS: Of 78 patients, 16 (20.5%) underwent MVS (caval and/or aortic replacement or reconstruction). On univariable analyses, transversal diameter, sagittal diameter, tumor volume, aorta- and cava-tumor contact angle, poor IGCCCG score, clinical stage III and preoperative positive markers were predictors of MVS (all p values ≤ 0.01). At multivariable analyses aorta- (cut-off 64°) and cava-tumor contact angle (cut-off 98°) and poor IGCCCG score represented the three most important predictors of MVS (all p values ≤ 0.05). The model constructed has a PPV 100%, NPV 87% and an accuracy of 88%.
CONCLUSIONS: Presence of aorta-tumor contact angle ≥ 64°, cava-tumor contact angle ≥ 98° and poor IGCCCG score identify correctly 9 out of 10 patients requiring MVS at the time of first PC-RPLND.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  PC-RPLND; Radiology; Testicular cancer; Vascular surgery

Mesh:

Year:  2021        PMID: 34731264     DOI: 10.1007/s00345-021-03870-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  12 in total

Review 1.  EAU guidelines on testicular cancer: 2011 update.

Authors:  Peter Albers; Walter Albrecht; Ferran Algaba; Carsten Bokemeyer; Gabriella Cohn-Cedermark; Karim Fizazi; Alan Horwich; Maria Pilar Laguna
Journal:  Eur Urol       Date:  2011-05-25       Impact factor: 20.096

2.  Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

Authors:  K Fizazi; S Tjulandin; R Salvioni; J R Germà-Lluch; J Bouzy; D Ragan; C Bokemeyer; A Gerl; A Fléchon; J S de Bono; S Stenning; A Horwich; J Pont; P Albers; U De Giorgi; M Bower; A Bulanov; G Pizzocaro; J Aparicio; C R Nichols; C Théodore; J T Hartmann; H J Schmoll; S B Kaye; S Culine; J P Droz; C Mahé
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

3.  Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.

Authors:  Christian Winter; David Pfister; Jonas Busch; Cigdem Bingöl; Ulrich Ranft; Mark Schrader; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Albers
Journal:  Eur Urol       Date:  2011-11-07       Impact factor: 20.096

Review 4.  Residual tumor resection (RTR).

Authors:  A Lusch; P Albers
Journal:  World J Urol       Date:  2016-12-21       Impact factor: 4.226

5.  Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer.

Authors:  Scott C Johnson; Zachary L Smith; Charles Nottingham; Zeyad R Schwen; Stephen Thomas; Elliot K Fishman; Nam Ju Lee; Philip M Pierorazio; Scott E Eggener
Journal:  Urology       Date:  2018-09-01       Impact factor: 2.649

6.  Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours.

Authors:  A Heidenreich; F Haidl; P Paffenholz; Ch Pape; U Neumann; D Pfister
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

7.  Vascular interventions during post-chemotherapy retroperitoneal lymph-node dissection for metastatic testis cancer.

Authors:  T J Christmas; G L Smith; R Kooner
Journal:  Eur J Surg Oncol       Date:  1998-08       Impact factor: 4.424

8.  Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections.

Authors:  E P Fox; T D Weathers; S D Williams; P J Loehrer; T M Ulbright; J P Donohue; L H Einhorn
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

Review 9.  Integration of surgery and systemic therapy: results and principles of integration.

Authors:  J P Donohue; I Leviovitch; R S Foster; J Baniel; P Tognoni
Journal:  Semin Urol Oncol       Date:  1998-05

10.  Additional surgical procedures and perioperative morbidity in post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer in two intermediate volume hospitals.

Authors:  Joost M Blok; Richard P Meijer; Henk G van der Poel; Axel Bex; Jeanette van Vooren; Japke J van Urk; Simon Horenblas; J L H Ruud Bosch
Journal:  World J Urol       Date:  2020-05-05       Impact factor: 4.226

View more
  2 in total

1.  Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility.

Authors:  Christian D Fankhauser; Luca Afferi; Sean P Stroup; Nicholas R Rocco; Kathleen Olson; Aditya Bagrodia; Fady Baky; Walter Cazzaniga; Erik Mayer; David Nicol; Ekrem Islamoglu; Stephane de Vergie; Ragheed Saoud; Scott E Eggener; Sebastiano Nazzani; Nicola Nicolai; Lee Hugar; Wade J Sexton; Deliu-Victor Matei; Ottavio De Cobelli; Joseph Cheaib; Phillip M Pierorazio; James Porter; Thomas Hermanns; Robert J Hamilton; Andreas Hiester; Peter Albers; Noel Clarke; Agostino Mattei
Journal:  World J Urol       Date:  2022-03-13       Impact factor: 4.226

2.  Special Issue on Testis Cancer.

Authors:  Daniel Nettersheim; Peter Albers
Journal:  World J Urol       Date:  2022-02       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.